T8885
Thrombin from human plasma
lyophilized powder, Suitable for routine use in the thrombin time test
Synonym(s):
Factor IIa
biological source
human plasma
Quality Level
form
lyophilized powder
packaging
vial of ≥10 NIH units
impurities
HIV, hepatitis B and hepatitis C, tested negative
UniProt accession no.
storage temp.
−20°C
Gene Information
human ... F2(2147)
Looking for similar products? Visit Product Comparison Guide
General description
Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects.
Application
Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study that compared efficacy and safety of low-molecular-weight heparins (LMWHs) to other anticoagulants as venous thromboembolism prophylaxis in major orthopedic surgery.
Biochem/physiol Actions
Serine protease that selectively cleaves Arg-Gly bonds in fibrinogen to form fibrin and fibrinopeptides A and B.
Preparation Note
When reconstituted with 1 ml H2O, one vial will contain 10 mg bovine serum albumin, 0.15 M NaCl and 0.05 M sodium citrate, pH 6.5
Analysis Note
The NIH assay procedure uses 0.2 ml diluted plasma (1:1 with saline) as a substrate and 0.1ml of thrombin sample (stabilized in a 1% buffered albumin solution) based on a modification of the method of Biggs. Only clotting times in the range of 15-25 seconds are used for determining thrombin concentrations.
Other Notes
Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard
View more information on thrombin at www.sigma-aldrich.com/enzymeexplorer.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
高风险级别生物产品--人源产品
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Diana M Sobieraj et al.
Pharmacotherapy, 32(9), 799-808 (2012-06-30)
To evaluate the comparative efficacy and safety of low-molecular-weight heparins (LMWHs) versus other anticoagulants as venous thromboembolism prophylaxis in major orthopedic surgery. Systematic review with meta-analysis of 37 randomized controlled trials. Patients undergoing total hip replacement, total knee replacement, or
Nathalie Busschaert et al.
Chembiochem : a European journal of chemical biology, 23(6), e202100670-e202100670 (2022-01-06)
The thrombin binding aptamer (TBA) is a 15-mer DNA oligonucleotide (5'-GGT TGG TGT GGT TGG-3'), that can form a stable intramolecular antiparallel chair-like G-quadruplex structure. This aptamer shows anticoagulant properties by interacting with one of the two anion binding sites
Michael Hultström et al.
Biomedicines, 10(6) (2022-06-25)
Hypercoagulation and endothelial dysfunction play central roles in severe forms of COVID-19 infections, but the molecular mechanisms involved are unclear. Increased plasma levels of the inflammatory cytokine and TIE2 receptor antagonist Angiopoietin-2 were reported in severely ill COVID-19 patients. In
Shenghui Huang et al.
Reproductive sciences (Thousand Oaks, Calif.), 29(4), 1170-1187 (2022-02-01)
The development of more efficacious, non-hormonal therapeutics for endometriosis is still an unmet medical need begging to be fulfilled. Growing evidence indicates that endometriotic lesions are wounds undergoing repeated tissue injury and repair, and, as such, platelets play an important
Deepti Sharma et al.
Communications biology, 5(1), 479-479 (2022-05-20)
Pathological retinal neovascularization (NV) is a clinical manifestation of various proliferative retinopathies, and treatment of NV using anti-VEGF therapies is not selective, as it also impairs normal retinal vascular growth and function. Here, we show that genetic deletion or siRNA-mediated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service